Will spironolactone (an antiandrogen medication) sufficiently block the effects of testosterone to prevent androgen-induced masculinization in a 12-year-old?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Spironolactone is not recommended for blocking testosterone in 12-year-olds to prevent masculinization. While spironolactone does have anti-androgenic properties, as it decreases testosterone production and competitively inhibits testosterone and dihydrotestosterone binding to androgen receptors in the skin 1, it is not FDA-approved for this purpose in children and lacks sufficient safety and efficacy data in this age group.

Key Considerations

  • The use of spironolactone in adults for acne treatment has shown moderate certainty evidence of effectiveness, with a greater proportion of patients achieving improvement in acne symptoms compared to placebo 1.
  • However, its use in children, particularly for blocking testosterone, is not supported by strong evidence and may pose significant risks, including menstrual irregularities, diuresis, breast tenderness, and potential effects on fetal development if used during pregnancy 1.
  • For adolescents with gender dysphoria seeking to prevent masculinization, GnRH analogues (such as leuprolide or histrelin) are considered the standard first-line treatment, as they effectively and reversibly suppress puberty by blocking the signals that stimulate testosterone production.

Clinical Recommendations

  • GnRH analogues should only be prescribed after comprehensive evaluation by specialists in pediatric endocrinology, adolescent medicine, and mental health who have experience in gender-affirming care.
  • The decision to use any puberty-blocking medication requires thorough discussion of potential benefits, risks, and alternatives with both the adolescent and their parents/guardians.
  • Ongoing psychological support and regular medical monitoring are essential components of a comprehensive care plan for adolescents undergoing gender-affirming treatment.

From the Research

Effectiveness of Spironolactone in Blocking Testosterone Effects

  • Spironolactone has been used as an antiandrogen medication to treat conditions such as hirsutism and female pattern hair loss 2, 3, 4.
  • It works by reducing adrenal androgen production and exerting competitive blockade on androgen receptors in target tissues 2.
  • Studies have shown that spironolactone can effectively decrease testosterone levels and improve symptoms of hyperandrogenism in women 3, 5.

Use of Spironolactone in Pediatric Patients

  • There is limited information available on the use of spironolactone in pediatric patients, particularly in blocking the effects of testosterone to prevent androgen-induced masculinization in a 12-year-old.
  • One study mentions the use of spironolactone in combination with testolactone to slow down pubertal progression and growth velocity in familial male precocious puberty, but it does not provide specific information on its effectiveness in blocking testosterone effects in a 12-year-old 6.

Safety and Efficacy of Spironolactone

  • Spironolactone has been shown to be safe and effective in treating hyperandrogenism in women, with a low incidence of side effects 3, 5, 4.
  • However, its use in pediatric patients requires careful consideration and monitoring due to the potential risks of feminization and other side effects.

Spironolactone as an Alternative to Other Antiandrogen Medications

  • Spironolactone has been evaluated as a relay for cyproterone acetate in the treatment of hyperandrogenism, and has been found to be an effective and well-tolerated alternative 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of hirsutism with spironolactone.

Clinics in endocrinology and metabolism, 1986

Research

Use of spironolactone in treatment of hirsutism.

Cleveland Clinic journal of medicine, 1990

Research

[Spironolactone as a relay for cyproterone acetate in hyperandrogenic women].

Gynecologie, obstetrique, fertilite & senologie, 2020

Research

Testolactone-associated high androgen levels, a pharmacologic effect or a laboratory artifact?

The Journal of clinical endocrinology and metabolism, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.